APRE · Aprea Therapeutics Inc. Common stock
View on chartInsiders & Stakes
| Oren Gilad President, CEO | ▲ Buy | Grant | 393,895 Shares held | 3/12/2026 | View profile |
| Marc Duey Director | ▲ Buy | Grant | 259,290 Shares held | 6/16/2026 | View profile |
| SCHADE CHRISTIAN S Director | ▲ Buy | Grant | 259,246 Shares held | 7/28/2022 | View profile |
| Coiante Scott M SVP, Chief Financial Officer | ▲ Buy | Grant | 145,065 Shares held | 7/28/2022 | View profile |
| Attar Eyal C. Chief Medical Officer | ▼ Sell | Tax Withholding | 57,233 Shares held | 6/3/2022 | View profile |
| Bernd R. Seizinger Director | ▲ Buy | Grant | 48,910 Shares held | 6/16/2026 | View profile |
| Korbel Gregory Alan Chief Business Officer | ▲ Buy | Grant | 45,762 Shares held | 7/28/2022 | View profile |
| Abrahmsen Lars B. SVP, Chief Scientific Officer | ▲ Buy | Grant | 43,700 Shares held | 3/10/2022 | View profile |
| John P. Hamill SrVP/CFO/Prin. Fin&Acctg. Off | ▲ Buy | Grant | 43,528 Shares held | 3/12/2026 | View profile |
| John B. Henneman III Director | ▲ Buy | Grant | 13,364 Shares held | 6/16/2026 | View profile |
| Rifat Pamukcu Director | ▲ Buy | Grant | 8,581 Shares held | 6/16/2026 | View profile |
| Mirza Nadeem Q. Chief Medical Officer | ▲ Buy | Grant | 6,730 Shares held | 5/1/2024 | View profile |
| Richard Peters Director | ▲ Buy | Grant | 6,254 Shares held | 6/16/2026 | View profile |
| Michael Grissinger Director | ▲ Buy | Grant | 6,024 Shares held | 6/16/2026 | View profile |
| Gabriela Gruia Director | ▲ Buy | Grant | 4,180 Shares held | 6/16/2026 | View profile |
| Jean-Pierre Bizzari Director | ▲ Buy | Grant | 4,180 Shares held | 6/16/2026 | View profile |
Transaction History
| Michael Grissinger | ▲ Buy | Grant | 3,135 | $0 | 6/16/2026 |
| Gabriela Gruia | ▲ Buy | Grant | 3,135 | $0 | 6/16/2026 |
| Richard Peters | ▲ Buy | Grant | 3,135 | $0 | 6/16/2026 |
| John B. Henneman III | ▲ Buy | Grant | 3,135 | $0 | 6/16/2026 |
| Jean-Pierre Bizzari | ▲ Buy | Grant | 3,135 | $0 | 6/16/2026 |
| Marc Duey | ▲ Buy | Grant | 3,135 | $0 | 6/16/2026 |
| Rifat Pamukcu | ▲ Buy | Grant | 3,135 | $0 | 6/16/2026 |
| Bernd R. Seizinger | ▲ Buy | Grant | 3,135 | $0 | 6/16/2026 |
| Oren Gilad | ▲ Buy | Grant | 20,175 | $0 | 3/12/2026 |
| John P. Hamill | ▲ Buy | Grant | 10,095 | $0 | 3/12/2026 |
| Oren Gilad | ▲ Buy | Open Market | 28,100 | $25K | 1/30/2026 |
| John P. Hamill | ▲ Buy | Open Market | 5,700 | $5K | 1/30/2026 |
| Marc Duey | ▲ Buy | Open Market | 21,459 | $25K | 12/10/2025 |
| John P. Hamill | ▲ Buy | Open Market | 5,000 | $6K | 12/10/2025 |
| Richard Peters | ▲ Buy | Grant | 1,045 | $0 | 6/5/2025 |
| Rifat Pamukcu | ▲ Buy | Grant | 1,045 | $0 | 6/5/2025 |
| John B. Henneman III | ▲ Buy | Grant | 1,045 | $0 | 6/5/2025 |
| Gabriela Gruia | ▲ Buy | Grant | 1,045 | $0 | 6/5/2025 |
| Michael Grissinger | ▲ Buy | Grant | 1,045 | $0 | 6/5/2025 |
| Marc Duey | ▲ Buy | Grant | 1,045 | $0 | 6/5/2025 |
| Jean-Pierre Bizzari | ▲ Buy | Grant | 1,045 | $0 | 6/5/2025 |
| Bernd R. Seizinger | ▲ Buy | Grant | 1,045 | $0 | 6/5/2025 |
| Oren Gilad | ▲ Buy | Open Market | 3,003 | $6K | 4/3/2025 |
| Oren Gilad | ▲ Buy | Open Market | 2,497 | $4K | 4/3/2025 |
| John P. Hamill | ▲ Buy | Grant | 3,365 | $0 | 3/27/2025 |
| Oren Gilad | ▲ Buy | Grant | 6,725 | $0 | 3/27/2025 |
| Oren Gilad | ▲ Buy | Open Market | 500 | $2K | 10/23/2024 |
| Marc Duey | ▼ Sell | Open Market | 6,462 | $30K | 10/18/2024 |
| Marc Duey | ▲ Buy | Open Market | 30,000 | $132K | 10/16/2024 |
| Oren Gilad | ▲ Buy | Open Market | 250 | $725 | 10/15/2024 |
| Oren Gilad | ▲ Buy | Open Market | 1,000 | $3K | 10/14/2024 |
| Marc Duey | ▲ Buy | Open Market | 190 | $490 | 10/14/2024 |
| John P. Hamill | ▲ Buy | Open Market | 50 | $123 | 10/11/2024 |
| Bernd R. Seizinger | ▲ Buy | Open Market | 10,000 | $27K | 10/11/2024 |
| Oren Gilad | ▲ Buy | Open Market | 150 | $381 | 10/10/2024 |
| John P. Hamill | ▲ Buy | Open Market | 450 | $1K | 10/10/2024 |
| Bernd R. Seizinger | ▲ Buy | Grant | 1,045 | $0 | 6/20/2024 |
| Rifat Pamukcu | ▲ Buy | Grant | 1,045 | $0 | 6/20/2024 |
| Richard Peters | ▲ Buy | Grant | 1,045 | $0 | 6/20/2024 |
| John B. Henneman III | ▲ Buy | Grant | 1,045 | $0 | 6/20/2024 |
| Michael Grissinger | ▲ Buy | Grant | 1,045 | $0 | 6/20/2024 |
| Marc Duey | ▲ Buy | Grant | 1,045 | $0 | 6/20/2024 |
| Mirza Nadeem Q. | ▲ Buy | Grant | 6,730 | $0 | 5/1/2024 |
| Oren Gilad | ▲ Buy | Grant | 6,725 | $0 | 3/28/2024 |
| John P. Hamill | ▲ Buy | Grant | 3,365 | $0 | 3/28/2024 |
| Bernd R. Seizinger | ▲ Buy | Open Market | 6,860 | $50K | 3/13/2024 |
| John B. Henneman III | ▲ Buy | Open Market | 6,860 | $50K | 3/13/2024 |
| Oren Gilad | ▲ Buy | Open Market | 2,000 | $15K | 3/13/2024 |
| John P. Hamill | ▲ Buy | Open Market | 1,010 | $7K | 3/13/2024 |
| Marc Duey | ▲ Buy | Grant | 500 | $0 | 8/23/2023 |
| John B. Henneman III | ▲ Buy | Grant | 500 | $0 | 8/23/2023 |
| Richard Peters | ▲ Buy | Grant | 500 | $0 | 8/23/2023 |
| Michael Grissinger | ▲ Buy | Grant | 500 | $0 | 8/23/2023 |
| Bernd R. Seizinger | ▲ Buy | Grant | 500 | $0 | 8/23/2023 |
| Rifat Pamukcu | ▲ Buy | Grant | 500 | $0 | 8/23/2023 |
| Bernd R. Seizinger | ▲ Buy | Open Market | 6,029 | $22K | 6/7/2023 |
| Bernd R. Seizinger | ▲ Buy | Open Market | 4,068 | $15K | 6/6/2023 |
| Oren Gilad | ▲ Buy | Grant | 4,000 | $0 | 3/9/2023 |
| John P. Hamill | ▲ Buy | Grant | 1,000 | $5K | 2/27/2023 |
| John P. Hamill | ▲ Buy | Grant | 269,879 | $0 | 1/30/2023 |
| Marc Duey | ▼ Sell | Other | 11,610 | $0 | 8/23/2022 |
| Rifat Pamukcu | ▼ Sell | Other | 49,280 | $0 | 8/23/2022 |
| Marc Duey | ▼ Sell | Other | 4,009,690 | $0 | 8/23/2022 |
| Rifat Pamukcu | ▼ Sell | Other | 271,870 | $0 | 8/23/2022 |
| Oren Gilad | ▼ Sell | Other | 6,045,100 | $0 | 8/23/2022 |
| Coiante Scott M | ▲ Buy | Grant | 60,800 | $0 | 7/28/2022 |
| Bernd R. Seizinger | ▲ Buy | Grant | 5,995 | $0 | 7/28/2022 |
| SCHADE CHRISTIAN S | ▲ Buy | Grant | 32,400 | $0 | 7/28/2022 |
| Richard Peters | ▲ Buy | Grant | 5,995 | $0 | 7/28/2022 |
| Rifat Pamukcu | ▲ Buy | Grant | 5,995 | $0 | 7/28/2022 |
| Korbel Gregory Alan | ▲ Buy | Grant | 24,300 | $0 | 7/28/2022 |
| John B. Henneman III | ▲ Buy | Grant | 5,995 | $0 | 7/28/2022 |
| Michael Grissinger | ▲ Buy | Grant | 5,995 | $0 | 7/28/2022 |
| Oren Gilad | ▲ Buy | Grant | 101,300 | $0 | 7/28/2022 |
| Marc Duey | ▲ Buy | Grant | 5,995 | $0 | 7/28/2022 |
| Coiante Scott M | ▼ Sell | Tax Withholding | 35,284 | $28K | 6/3/2022 |
| Korbel Gregory Alan | ▼ Sell | Tax Withholding | 8,390 | $7K | 6/3/2022 |
| Attar Eyal C. | ▼ Sell | Tax Withholding | 32,667 | $26K | 6/3/2022 |
| SCHADE CHRISTIAN S | ▼ Sell | Tax Withholding | 65,770 | $53K | 6/3/2022 |
| SCHADE CHRISTIAN S | ▲ Buy | Open Market | 37,500 | $24K | 5/18/2022 |
| Bernd R. Seizinger | ▲ Buy | Open Market | 50,000 | $36K | 5/18/2022 |
| Korbel Gregory Alan | ▼ Sell | Tax Withholding | 1,989 | $4K | 3/10/2022 |
| Attar Eyal C. | ▲ Buy | Grant | 42,900 | $0 | 3/10/2022 |
| Abrahmsen Lars B. | ▲ Buy | Grant | 24,700 | $0 | 3/10/2022 |
| Coiante Scott M | ▲ Buy | Grant | 42,900 | $0 | 3/10/2022 |
| Korbel Gregory Alan | ▲ Buy | Grant | 16,000 | $0 | 3/10/2022 |
| SCHADE CHRISTIAN S | ▲ Buy | Grant | 100,100 | $0 | 3/10/2022 |
| Attar Eyal C. | ▼ Sell | Open Market | 36,000 | $62K | 2/28/2022 |
| SCHADE CHRISTIAN S | ▼ Sell | Tax Withholding | 21,644 | $38K | 2/25/2022 |
| Korbel Gregory Alan | ▼ Sell | Tax Withholding | 1,326 | $2K | 2/25/2022 |
| Coiante Scott M | ▼ Sell | Tax Withholding | 14,817 | $26K | 2/25/2022 |
| Korbel Gregory Alan | ▲ Buy | Option Exercise | 27,500 | $25K | 12/1/2021 |
| Korbel Gregory Alan | ▼ Sell | Open Market | 27,500 | $109K | 12/1/2021 |
| Korbel Gregory Alan | ▲ Buy | Option Exercise | 27,500 | $25K | 11/1/2021 |
| Korbel Gregory Alan | ▼ Sell | Open Market | 27,500 | $138K | 11/1/2021 |
| Abrahmsen Lars B. | ▲ Buy | Option Exercise | 50,000 | $46K | 10/1/2021 |
| Abrahmsen Lars B. | ▼ Sell | Open Market | 50,000 | $244K | 10/1/2021 |
| Korbel Gregory Alan | ▲ Buy | Option Exercise | 27,500 | $25K | 10/1/2021 |
| Korbel Gregory Alan | ▼ Sell | Open Market | 27,500 | $134K | 10/1/2021 |
| Korbel Gregory Alan | ▲ Buy | Option Exercise | 27,500 | $25K | 9/20/2021 |
| Abrahmsen Lars B. | ▲ Buy | Option Exercise | 25,000 | $23K | 9/20/2021 |
| Abrahmsen Lars B. | ▼ Sell | Open Market | 25,000 | $124K | 9/20/2021 |
| Korbel Gregory Alan | ▼ Sell | Open Market | 27,500 | $137K | 9/20/2021 |
| Korbel Gregory Alan | ▼ Sell | Open Market | 5,460 | $27K | 9/20/2021 |
| Attar Eyal C. | ▼ Sell | Open Market | 15,968 | $75K | 9/16/2021 |
| Korbel Gregory Alan | ▼ Sell | Tax Withholding | 1,724 | $8K | 9/10/2021 |
| Korbel Gregory Alan | ▼ Sell | Tax Withholding | 1,149 | $5K | 8/25/2021 |
| Coiante Scott M | ▼ Sell | Tax Withholding | 7,534 | $30K | 8/25/2021 |
| Attar Eyal C. | ▼ Sell | Tax Withholding | 9,032 | $36K | 8/25/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Aprea Therapeutics Announces October Conference Presentations
Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.
Aprea Therapeutics Announces October Conference Presentations. Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.